CN117396519A - 肾脏活性融合蛋白以及使用其的治疗方法 - Google Patents

肾脏活性融合蛋白以及使用其的治疗方法 Download PDF

Info

Publication number
CN117396519A
CN117396519A CN202280035932.2A CN202280035932A CN117396519A CN 117396519 A CN117396519 A CN 117396519A CN 202280035932 A CN202280035932 A CN 202280035932A CN 117396519 A CN117396519 A CN 117396519A
Authority
CN
China
Prior art keywords
compound
fusion protein
gly
amino acid
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280035932.2A
Other languages
English (en)
Chinese (zh)
Inventor
基思·布沙尔
杰弗里·威廉·亨特
Jr·布鲁斯·A·安德里安
圣光·金
朱利安·钱德勒
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alexion Pharmaceuticals Inc
Original Assignee
Alexion Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alexion Pharmaceuticals Inc filed Critical Alexion Pharmaceuticals Inc
Priority claimed from PCT/US2022/030658 external-priority patent/WO2022251168A1/en
Publication of CN117396519A publication Critical patent/CN117396519A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/624—Disulfide-stabilized antibody (dsFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • External Artificial Organs (AREA)
CN202280035932.2A 2021-05-25 2022-05-24 肾脏活性融合蛋白以及使用其的治疗方法 Pending CN117396519A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163192835P 2021-05-25 2021-05-25
US63/192,835 2021-05-25
PCT/US2022/030658 WO2022251168A1 (en) 2021-05-25 2022-05-24 Kidney active fusion proteins and methods of treatment using the same

Publications (1)

Publication Number Publication Date
CN117396519A true CN117396519A (zh) 2024-01-12

Family

ID=84178944

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280035932.2A Pending CN117396519A (zh) 2021-05-25 2022-05-24 肾脏活性融合蛋白以及使用其的治疗方法

Country Status (10)

Country Link
US (1) US20240262877A1 (https=)
EP (1) EP4347666A4 (https=)
JP (2) JP2024520421A (https=)
KR (1) KR20240013770A (https=)
CN (1) CN117396519A (https=)
AU (1) AU2022283254A1 (https=)
BR (1) BR112023024627A2 (https=)
CA (1) CA3177162A1 (https=)
IL (1) IL308754A (https=)
MX (1) MX2023014037A (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL301713A (en) * 2020-10-05 2023-05-01 Alexion Pharma Inc Methods for treating dermatomyositis

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1218409A2 (en) * 2000-03-13 2002-07-03 St. Vincent's Hospital (Melbourne) Limited Factor-h related protein 5 (fhr-5) and antibodies thereto
US7759304B2 (en) * 2006-06-21 2010-07-20 Regents Of The University Of Colorado Targeting complement factor H for treatment of diseases
US9815876B2 (en) * 2010-03-05 2017-11-14 Omeros Corporation Chimeric inhibitor molecules of complement activation
CA2920293A1 (en) * 2013-08-16 2015-02-19 Alexion Pharmaceuticals, Inc. Treatment of graft rejection by administering a complement inhibitor to an organ prior to transplant
WO2018075462A1 (en) * 2016-10-17 2018-04-26 Medical University Of South Carolina Compositions and methods for treating and preventing transplant-associated injury

Also Published As

Publication number Publication date
JP2025116068A (ja) 2025-08-07
JP2024520421A (ja) 2024-05-24
IL308754A (en) 2024-01-01
EP4347666A1 (en) 2024-04-10
EP4347666A4 (en) 2025-07-16
BR112023024627A2 (pt) 2024-02-20
AU2022283254A9 (en) 2023-12-07
KR20240013770A (ko) 2024-01-30
US20240262877A1 (en) 2024-08-08
CA3177162A1 (en) 2022-11-25
AU2022283254A1 (en) 2023-11-30
MX2023014037A (es) 2024-01-15

Similar Documents

Publication Publication Date Title
JP7444886B2 (ja) 補体関連疾患のための融合タンパク質構築物
JP7685737B2 (ja) 疾患の治療または予防に用いるためのファクター１およびファクター２タンパク質、およびその阻害剤
JP6812551B2 (ja) 前立腺特異的膜抗原結合タンパク質
TWI598361B (zh) Ｃｘ３ｃｒ１－結合多肽
EP1888641B1 (en) Serum albumin binding proteins
KR101819135B1 (ko) 당화 vegf 디코이 수용체 융합 단백질
US20220009979A1 (en) Fusion proteins and methods of treating complement dysregulation using the same
US20250353915A1 (en) Antibodies to galectin-3 and methods of use thereof
JP6914193B2 (ja) Ｂｄｎｆを含む融合蛋白質
KR20120089863A (ko) “개선된 당화반응 최종 생성물에 대한 수용체”에 결합하기 위한 폴리펩타이드 및 이를 포함하는 조성물 및 방법
JP2015505843A (ja) 可溶性ＩＧＦレセプターＦｃ融合タンパク質およびその使用
CA3195315A1 (en) Compositions and methods for selective depletion of target molecules
CN106687478A (zh) 新的抗人Tie‑2抗体
WO2020041638A1 (en) Complement factor h and fc binding domain fusion proteins
JP2025116068A (ja) 腎臓活性融合タンパク質及びそれを使用する治療方法
AU2012358248B2 (en) Serum amyloid P-antibody fusion proteins
WO2022251168A9 (en) Kidney active fusion proteins and methods of treatment using the same
EA053282B1 (ru) Активные в почках слитые белки и способы лечения с их применением
EP3808847A1 (en) Apj antibody, fusion protein thereof with elabela, and pharmaceutical compositions and use thereof
WO2021154216A1 (en) Fusion proteins and methods of treating complement dysregulation using the same
RU2824402C2 (ru) Конструкции слитого белка для заболевания, связанного с комплементом
RU2802307C2 (ru) C3-связывающие агенты и способы их применения
WO2025098472A1 (zh) 融合蛋白及其医药用途
CN115551529A (zh) 增强房水流出并降低眼内压的方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination